Switzerland-based biotechnology company ESBATech has announced encouraging preclinical results, which demonstrate efficacy of topical ESBA105, an antitumor necrosis factor single-chain antibody fragment, in a model for choroidal neovascularization.
Under the terms of this collaboration, Proteros will provide multi-disciplinary research teams with the aim of generating multiple advanced lead series inhibiting a novel proprietary target protein. In
Dr Boman comes to Acucela as a veteran of several West Coast biotech companies, most recently overseeing clinical development and regulatory affairs for Cell Therapeutics in Seattle. She
Medtronic plans to launch the Endeavor drug-eluting stent (DES) immediately following the authorization of reimbursement which is expected on May 1, 2009. Following the launch in Japan, the
Oncolytics Biotech, a biopharmaceutical company, has completed patient enrollment in its UK clinical trial to evaluate the anti-tumor effects of intravenous administration of Reolysin in combination with gemcitabine
Patheon and Swiftwater will combine resources to provide regulatory consulting services to clients. Swiftwater Group can assist Patheon clients as they navigate through the regulatory process, by providing
Adventrx Pharmaceuticals, a biopharmaceutical company, has granted Shin Poong Pharmaceutical exclusive rights in South Korea to make, use and sell ANX-514, one of its two lead product candidates.
Ms Eastham will join Geron’s existing board members: board chair Alexander Barkas, Edward Fritzky, Charles Homcy, Thomas Kiley, Patrick Zenner and Geron’s president and CEO, Thomas Okarma. Ms
The new round of funding includes participation from Forbion Capital Partners, HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners, Giza Venture Capital and individual investors. Pathway will
Xcellerex, a developer and marketer of biomolecules, along with three collaborators, has received an $11 million Phase II contract from the Defense Threat Reduction Agency – Joint Science
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.